阿仑膦酸治疗绝经后骨质疏松症

目的 :观察阿仑膦酸治疗绝经后骨质疏松症的疗效。方法 :绝经后骨质疏松症妇女 70例 ,随机分为阿仑膦酸组 40例 (年龄 63a±s 4a ,绝经年限15a± 5a) ;对照组 30例 (年龄 63a± 5a ,绝经年限 13a± 6a)。 2组均应用碳酸钙_维生素D 0 .6gpo ,qn ;阿仑膦酸组加阿仑膦酸 10mg ,po ,qd ,晨空腹服 ,疗程均 6mo。每组用药前后检测腰椎、髋部骨密度 (BMD) ,血清碱性磷酸酶 (ALP)、骨钙素(BGP)、酸性磷酸酶 (ACP)。结果 :用药后治疗组血清ALP ,BGP ,ACP显著下降 ,腰椎、髋部BMD明显增高 ,骨痛改善 ,总疗效为 88% ,对照组总疗效5 0 % (P <0 .0 1) ,不良反应轻。结论 :阿仑膦酸是治疗绝经后妇女骨质疏松症的安全、有效的药物

Alendronate in treatment of postmenopausal osteoporosis

AIM: To evaluate the clinical effects of alendronate in the treatment of postmenopausal osteoporosis(OP). METHODS: Seventy women with postmenopausal OP were randomly divided into the alendronate group of 40 patients (age 63 a±s 4 a, menopausal years 15 a±5 a) and the control group of 30 patients (age 63 a±5 a, menopausal years 13 a±6 a). All patients of both groups took calcium carbonate_vitamin D) (Caltrate_D) 0.6 g, po, qn, while those of the alendronate group also took alendronate before breakfast with empty stomach, 10 mg, po, qd, for 6 mo. Before and after being treated, patients of both groups were checked with BMD of L 2_L 4 and femur bone, ALP, BGP, ACP. RESULTS: ALP, BGP, ACP of the alendronate group decreased notably, BMD of L 2_L 4 and femur bone increased too, boneache improved. The total effect was 88%, while the control group was 50%. There was significant difference between two groups (P<0.01). The adverse reaction was mild. CONCLUSION: Alendronate is an effective and safe drug in the treatment of postmenopausal OP.